

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY

The American Board of Psychiatry and Neurology, Inc. (ABPN) is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes.

The ABPN designs and develops the initial neurology certification examination to assess the knowledge and reasoning skills needed to provide high quality patient care in the broad domain of the specialty. It utilizes two-dimensional content specifications. Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on ischemic stroke could focus on treatment, or it could focus on systems-based practice.

Candidates should use the detailed content outline as a guide to prepare for a certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format.

For more information, please contact us at questions@abpn.org or visit our website at www.abpn.org



A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY Content Blueprint

Number of	Number of questions: 400		
	Dimension 1		
	Neurologic Disorders and Topics		
		T	
01.	Headache and pain disorders	4-6%	
02.	Epilepsy and episodic disorders	8-12%	
03.	Sleep disorders	3-5%	
04.	Genetic and developmental disorders	6-8%	
05.	Vascular neurology	8-12%	
06.	Neuromuscular diseases	9-13%	
07.	Movement disorders	8-12%	
08.	Demyelinating diseases	7-11%	
09.	Neuroinfectious diseases	2-4%	
10.	Brain and spinal trauma and spinal diseases	2-4%	
11.	Neuro-ophthalmologic and neuro-otologic disorders	2-4%	
12.	Metabolic diseases, nutritional deficiency states, and disorders due to toxins,	3-5%	
	drugs, and physical agents		
13.	Neuro-oncologic disorders	1-3%	
14.	Behavioral neurology and neurocognitive disorders	7-9%	
15.	Psychiatric disorders	5-7%	
16.	Autonomic nervous system disorders	1-2%	
17.	Questions not associated with a specific neurologic disorder	1-3%	
18.	Neuroimmunologic and paraneoplastic CNS disorders	1-3%	



A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY Content Blueprint

Number of	lumber of questions: 400		
	Dimension 2		
	Physician Competencies and Mechanisms		
A.	Neuroscience and mechanism of disease	22-28%	
В.	Clinical aspects of neurologic disease	17-23%	
C.	Diagnostic procedures	17-23%	
D.	Treatment/Management	22-28%	
E.	Interpersonal and communication skills	2-3%	
F.	Professionalism	2-3%	
G.	Practice-based learning and improvement	2-3%	
Н.	Systems-based practice	2-3%	



A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY Content Outline

Nun	nber of	f items:	400
			Dimension 1
			Neurologic Disorders and Topics
01.	Heada	ache and	d pain disorders
	A.	Heada	che
		01.	Primary headaches
			a. Migraine
			b. Tension-type headache
			c. Cluster headache and other trigeminal autonomic cephalalgias
			xx. Other (exertional headache, etc.)
		02.	Secondary headaches
			a. Headache due to head and neck trauma (posttraumatic headache)
			 Headache due to cranial or cervical vascular disorder (thunderclap headache, reversible cerebral vasoconstriction syndrome (RCVS), arterial dissection, cerebral hemorrhage, ischemia)
			 Headache due to nonvascular intracranial disorder (hydrocephalus, idiopathic intracranial hypertension, increased intracranial pressure and cerebral edema, low-CSF-pressure headaches, tumors)
			d. Headache due to infection
			e. Headache due to a substance or its withdrawal
			f. Headache or facial pain due to disorder of cranium, neck, eyes, ears, nose, sinuses, and teeth
			g. Headache due to psychiatric disorder
		03.	Cranial neuralgia, central and primary facial pain (trigeminal neuralgia, idiopathic facial pain, post-herpetic neuralgia)
	В.	Pain di	sorders
		01.	Central pain syndromes (thalamic, phantom, etc.)
		02.	Complex regional pain syndromes
02.	Epilep	osy and	episodic disorders
	A.	Genera	alized seizures
		01.	Tonic-clonic (in any combination)
		02.	Absence
			a. Typical
			b. Atypical
			c. Absence with special features
		03.	<u> </u>
			Clonic
		05.	Tonic



06.	Atonic
07.	r sreather a
B. Focal s	eizures
01.	Aware
02.	Impaired awareness
03.	
XX.	Other
C. Electro	clinical syndromes
01.	Neonatal period
	a. Self-limited neonatal seizures
	b. Early myoclonic encephalopathy
	c. Early infantile epileptic encephalopathy (Ohtahara syndrome)
	d. Symptomatic neonatal seizures
	xx. Other early infantile epileptic encephalopathy
02.	Infancy
	a. West syndrome (infantile spasms)
	b. Myoclonic epilepsy in infancy
	c. Self-limited nonfamilial infantile epilepsy
	d. Self-limited familial infantile epilepsy
	e. Severe myoclonic epilepsy of infancy (Dravet syndrome)
	f. Myoclonic encephalopathy in nonprogressive disorders
	g. Epilepsy of infancy with migrating focal seizures
	h. Hemiconvulsion-hemiplegia-epilepsy syndrome
	xx. Other developmental epileptic encephalopathies with onset in infancy
03.	Childhood
	a. Febrile seizures plus
	b. Self-limited epilepsy with autonomic seizures (Panayiotopoulos syndrome)
	c. Epilepsy with myoclonic-atonic seizures (Doose syndrome)
	d. Childhood epilepsy with centrotemporal spikes
	e. Autosomal dominant sleep-related hypermotor epilepsy
	f. Childhood occipital epilepsy (Gastaut type)
	g. Epilepsy with myoclonic absences
	h. Lennox-Gastaut syndrome
	i. Epileptic encephalopathy with continuous spike-and-wave during sleep
	j. Childhood absence epilepsy
	k. Acquired epileptic aphasia, including Landau-Kleffner syndrome
	xx. Other developmental epileptic encephalopathies with onset in childhood
04.	Adolescence through adult
	a. Juvenile absence epilepsy
	b. Juvenile myoclonic epilepsy
	c. Epilepsy with generalized tonic-clonic seizures alone
	,



		d. Autorough descinant acitema with auditem feature.
		d. Autosomal dominant epilepsy with auditory features
		xx. Other familial temporal lobe epilepsies
	05.	•
	06.	
	07.	<u> </u>
D.	•	pecific age relationship
		Familial focal epilepsy with variable foci
		Reflex epilepsies
	03.	Progressive myoclonus epilepsies
	04.	Mesial temporal lobe epilepsy with hippocampal sclerosis
	05.	Rasmussen syndrome
	06.	Focal emotional (gelastic) seizures with hypothalamic hamartoma
E.	Epileps	sies attributed to and organized by structural-metabolic causes
	01.	Structural (including tumors, vascular malformations)
	02.	Infection
	03.	Trauma
	04.	Perinatal insults
	05.	Malformations of cortical development (including neurocutaneous syndromes)
	06.	Mitochondrial and metabolic disorders
	07.	Stroke
	08.	Genetic epilepsies
F.	Epileps	sies of unknown cause
G.	Condit	ions with epileptic seizures traditionally not diagnosed as a form of epilepsy
	01.	Benign neonatal seizures
	02.	Febrile seizures
	03.	Provoked seizures
Н.	Nonep	ileptic paroxysmal disorders
	01.	Syncope and anoxic seizures
	02.	Functional neurologic nonepileptic seizures and other behavioral, psychological, and psychiatric
		disorders
	03.	Sleep-related conditions
	04.	Paroxysmal movement disorders
	05.	Migraine-associated disorders
	06.	Miscellaneous events
	XX.	Other
l.	Status	epilepticus
	01.	Convulsive
	02.	Nonconvulsive
	03.	Focal motor
	04.	Tonic status
	05.	Febrile
•		



03. Sleep disorders A. Insomnia 01. Psychological insomnia 02. Inadequate sleep hygiene B. Sleep-disordered breathing 01. Obstructive sleep apnea 02. Central apnea syndromes 03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake phase disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder 03. REM-related parasomnias c. Nightmare disorder 04. Reurrent isolated sleep paralysis c. Nightmare disorder 05. Sleep enuresis d. Parasomnia de Exploding head syndrome b. Sleep-related hullcinations c. Sleep enuresis d. Parasomnia f. Unspecified parasomnia	0.0	Defendance and according to the control of the cont
A. Insomnia O1. Psychological insomnia O2. Inadequate sleep hygiene B. Sleep-disordered breathing O1. Obstructive sleep apnea O2. Central apnea syndromes O3. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence O1. Narcolepsy (with and without cataplexy) O2. Kleine-Levin syndrome O3. Hypersomnia due to a medical condition O4. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders O1. Delayed sleep-wake phase disorder O2. Advanced sleep-wake phase disorder O3. Irregular sleep-wake rhythm disorder O4. Non-24-hour sleep-wake phase disorder E. Parasomnias O1. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder O2. REM-related parasomnias a. REM sleep behavior disorder 03. C. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related ead syndrome c. Sleep entresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Unspecified parasomnia		·
01. Psychological insomnia 02. Inadequate sleep hygiene B. Sleep-disordered breathing 01. Obstructive sleep apnea 02. Central apnea syndromes 03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Unspecified parasomnia	-	
02. Inadequate sleep hygiene 8. Sleep-disordered breathing 01. Obstructive sleep apnea 02. Central apnea syndromes 03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep pralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep annesis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Sleep-related movement disorders		
B. Sleep-disordered breathing 01. Obstructive sleep apnea 02. Central apnea syndromes 03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake phase disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Sleep-related movement disorders		. •
01. Obstructive sleep apnea 02. Central apnea syndromes 03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake phase disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. RE M sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Sleep-related movement disorders		
02. Central apnea syndromes 03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake phase disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Sleep-related movement disorders		
03. Sleep-related hypoventilation disorders C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Sleep-related movement disorders		
C. Central disorders of hypersomnolence 01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake phase disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia f. Unspecified parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
01. Narcolepsy (with and without cataplexy) 02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
02. Kleine-Levin syndrome 03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake phase disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
03. Hypersomnia due to a medical condition 04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
04. Insufficient sleep syndrome D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		·
D. Circadian rhythm sleep-wake disorders 01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		• • • • • • • • • • • • • • • • • • • •
01. Delayed sleep-wake phase disorder 02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		' '
02. Advanced sleep-wake phase disorder 03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
03. Irregular sleep-wake rhythm disorder 04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		<u> </u>
04. Non-24-hour sleep-wake phase disorder E. Parasomnias 01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
E. Parasomnias O1. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder O2. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder O3. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
01. Non-REM-related parasomnias a. Arousal disorders i. Sleepwalking ii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		·
a. Arousal disorders i. Sleepwalking ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
i. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders	01.	
ii. Sleep terrors iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
iii. Confusional arousals b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
b. Sleep-related eating disorder 02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		•
02. REM-related parasomnias a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
a. REM sleep behavior disorder b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders	02.	
b. Recurrent isolated sleep paralysis c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		•
c. Nightmare disorder 03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		•
03. Other a. Exploding head syndrome b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders	03.	
b. Sleep-related hallucinations c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		a. Exploding head syndrome
c. Sleep enuresis d. Parasomnia due to a general medical disorder e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
e. Medication/substance-related parasomnia f. Unspecified parasomnia F. Sleep-related movement disorders		
f. Unspecified parasomnia F. Sleep-related movement disorders		d. Parasomnia due to a general medical disorder
F. Sleep-related movement disorders		e. Medication/substance-related parasomnia
		•
	F. Sleep-	related movement disorders
01. Periodic limb movements of sleep	01.	Periodic limb movements of sleep
02. Sleep-related limb cramps	02.	Sleep-related limb cramps
03. Sleep-related bruxism	03.	Sleep-related bruxism



		Benign myoclonus of infancy
G.		isorders in other conditions
	01.	Sleep disturbances in movement conditions
		a. Parkinson disease
		b. Multisystem atrophy
		c. Dementia with Lewy bodies
		d. Spinocerebellar degeneration
		e. Huntington disease
	02.	Neuromuscular disorders (ALS, MG, MD, and others)
	03.	Alzheimer disease
	04.	Effects of sleep disorders on cardiovascular/cerebrovascular risk factors
		a. Hypertension
		b. Atrial fibrillation
		c. Congestive heart failure
		d. Myocardial infarction
		e. Stroke
	05.	Myotonic dystrophy
04. Gene	tic and d	evelopmental disorders
A.	Inherit	ed metabolic disorders
	01.	Disorders of amino acid metabolism
		a. Phenylketonuria
		b. Nonketotic hyperglycinemia
		c. Other
	02.	Disorders of urea cycle metabolism
		a. Ornithine transcarbamylase
		b. Other
	03.	Disorders of sulfur amino acids
		a. Homocystinuria
		b. Other
	04.	Disorders of amino acid transport
		a. Hartnup disease
		b. Lowe syndrome
		c. Other
	05.	Disorders of carbohydrate metabolism and transport
		a. Galactosemia
		b. Glucose transporter deficiency
		c. Other
	06.	Organic acidurias
		a. Methylmalonic acidurias
		b. Glutaric acidurias
		c. Other
1		



	07. Disorders of fatty acid oxidation			
	08. Disorders of purine metabolism			
	a. Lesch-Nyhan syndrome			
	b. Other			
	09. Porphyria			
	 Disorders of iron metabolism (including pantothenate kinase-associated neurodegeneration (PKAN)) 			
	XX. Other			
B. Lys	sosomal disorders			
	01. Glycogen storage diseases			
	a. Pompe disease			
	b. Mucopolysaccharidoses			
	c. Other			
	02. Gangliosidoses			
	a. Tay-Sachs disease			
	b. Other			
	03. Gaucher disease			
	04. Fabry disease			
	05. Niemann-Pick disease			
	06. Neuronal ceroid lipofuscinosis			
	XX. Other			
C. Lei	ukodystrophies			
	01. Adrenoleukodystrophy			
	02. Pelizaeus-Merzbacher disease			
	03. Canavan disease			
	04. Alexander disease			
	05. Metachromatic leukodystrophy			
	06. Krabbe disease			
	XX. Other			
D. Ad	ditional disorders			
	01. Rett syndrome			
	02. Mitochondrial disorders			
	03. Peroxisomal disorders			
	XX. Other			
E. Ch	romosomal disorders			
	01. Autosomal abnormalities			
	a. Down syndrome (trisomy 21)			
	b. Trisomy 13			
	c. Cri du chat syndrome			
	d. Duplication/deletion			
	i. Angelman syndrome			
	0 1 1			



11 2 1 111111
ii. Prader-Willi
iii. Other
e. Williams syndrome
xx. Other
02. X-chromosomal disorders
a. Fragile X syndrome
b. Other
03. Other
F. Disorders of brain and spine development
01. Anencephaly
02. Myelomeningocele and encephalocele
03. Chiari malformations
04. Other cord dysraphism
a. Syringomyelia
b. Diastematomyelia
c. Tethered cord
05. Cerebellar malformations
06. Skull malformations, including craniosynostosis
a. Joubert syndrome
b. Dandy Walker and variants
c. Other
07. Brain malformations
a. Holoprosencephaly
b. Septo-optic dysplasia
c. Schizencephaly
d. Lissencephaly and other migrational abnormalities
e. Agenesis of the corpus callosum
f. Hemimegalencephaly
08. Microencephaly and micrencephaly
09. Macrencephaly, megalencephaly, and other overgrowth syndromes
10. Hydrocephalus
11. Cystic malformations (arachnoid, colloid, pineal, dermoid)
G. Neurocutaneous syndromes
01. Neurofibromatosis 1 and 2
02. Tuberous sclerosis
03. Sturge-Weber syndrome
04. Ataxia-telangiectasia
05. Von Hippel-Lindau disease
06. Incontinentia pigmenti
XX. Other
H. Cerebral palsy



		01.	'
		02.	Dyskinetic/dystonic
		03.	Ataxic
		XX.	Other
05.	Vascu	lar neur	ology
	A.	Ischem	nic stroke (cerebral infarction and transient ischemic attack)
		01.	Atherosclerosis
			a. Large-artery
			b. Small-artery
		02.	Cardioembolic
		03.	Arterial dissection
		04.	Other vasculopathies, including vasculitis
			a. Noninflammatory
			b. Infectious
			c. Inflammatory
		05.	Spinal cord infarction/ischemia
		XX.	Other
	В.	Intrace	erebral hemorrhage
			Chronic hypertension
		02.	Vascular malformations
		03.	Bleeding diatheses and antithrombotic agents
		04.	Cerebral amyloid angiopathy
		05.	Hemorrhagic tumors
		06.	Pituitary apoplexy
		07.	<u>c</u>
			Other
	C.	Subara	achnoid hemorrhage
			Aneurysm
		02.	Vascular malformations
			Complications (including vasospasm)
			Trauma
	D.	Cerebr	al venous thrombosis
		01.	0 , 1
		02.	71 0 71 7
	E.		ible cerebrovascular constriction syndrome (RCVS) and posterior reversible encephalopathy
			me (PRES)
	F.		cell disease
	G.	•	tured brain aneurysm or unruptured vascular malformation
	Н.	CADAS	IIL .
	XX.	Other	
06.	Neuro	muscul	ar diseases



A. Motor	neuron disorders
	Sporadic
01.	a. Amyotrophic lateral sclerosis (ALS)
	i. Progressive muscular atrophy (PMA)
	ii. Primary lateral sclerosis (PLS)
	iii. Progressive bulbar palsy
02.	Genetic
	a. Familial amyotrophic lateral sclerosis
	b. Spinal muscular atrophy
	c. Spinal and bulbar muscular atrophy (SBMA)
	d. Tay-Sachs disease
	e. Distal hereditary motor neuropathy
03.	Focal, including monomelic amyotrophy (Hirayama disease)
04.	Paraneoplastic
05.	Toxic
	a. Lathyrism
06.	Infectious
	a. Polio
	b. Rabies
	c. West Nile virus
	d. Tetanus
	e. Enterovirus D68 (EV-D68)
	root disorders
01.	Cervical
02.	Thoracic
03.	Lumbosacral
04.	Polyradiculopathy
05.	Specific etiologies
	a. Diabetes
	b. Segmental herpes zoster and post-herpetic neuralgia
	c. Infectious
	d. Neoplastic
	e. Degenerative/trauma
00	xx. Other
O6.	Myeloneuropathy
C. Plexopa	atries Brachial
01.	
	a. Traumatic (neonatal, penetrating injury) b. Radiation-induced
	c. Neuralgic amyotrophy (brachial neuritis)
	d. Hereditary neuralgic amyotrophy
	a. Herealtary hearaigic annyotrophry



_	Nia and lastic
e.	Neoplastic
f.	Neurogenic thoracic outlet syndrome
XX.	Other
02. Lumb	
a.	Traumatic (hematoma, ischemic)
b.	Radiation-induced
C.	Diabetic radiculoplexus neuropathy
d.	Neoplastic
XX.	Other
	erve disorders
	oneuropathies
a.	Median
b.	Ulnar
	i. at the wrist
	ii. at the elbow
C.	Radial
d.	Musculocutaneous
e.	Axillary
f.	Spinal accessory
g.	Suprascapular
<u>h.</u>	Sciatic
i.	Peroneal (fibular)
j.	Tibial
k.	Femoral
l.	Obturator
m.	Facial
n.	Trigeminal
0.	Lateral femoral cutaneous (meralgia paresthetica)
XX.	Other
	Diehotie
a.	Diabetic
b.	Vasculitic
C.	Inflammatory
d.	Genetic
e. f.	Neoplastic
	Infectious
-	neuropathy Lloraditany
a.	Hereditary
	i. Demyelinating
	(a) CMT1a
	(b) CMTX



(-)	Handitan and the state of the s
(c)	Hereditary neuropathy with tendencies to pressure palsy (HNPP)
(d)	Refsum disease
(e)	Metachromatic leukodystrophy
ii. Axon los	
(a)	CMT2
(b)	Adrenoleukodystrophy
	loid polyneuropathy
	c neuropathy
b. Acquired	
i. Immune	mediated
(a)	Guillain-Barré syndrome
	(i) Acute inflammatory demyelinating polyneuropathy (AIDP)
	(ii) Miller Fisher variant (GQ1b antibody)
	(iii) Acute motor axonal neuropathy (AMAN)
	(iv) Acute motor and sensory axonal neuropathy (AMSAN)
	(v) Pharyngeal-cervical-brachial (PCB)
(b)	Chronic inflammatory demyelinating polyneuropathy (CIDP)
(c)	Multifocal mononeuropathy with conduction block
(d)	Distal acquired demyelinating symmetric neuropathy (DADS)
(e)	Multifocal acquired demyelinating sensory and motor polyneuropathy
	(MADSAM)
(f)	Paraneoplastic
(g)	Amyloidosis
(h)	Sarcoidosis
(i)	Paraproteinemic
ii. Metabol	lic
(a)	Diabetic
(b)	Nutritional
	(i) Vitamin B6 deficiency
	(ii) Vitamin B12 deficiency
	(iii) Copper deficiency
	(iv) Alcohol
	(v) Hypervitaminosis B6
	(xx) Other
(c)	Critical illness
iii. Toxic	
(a)	Arsenic, lead, thallium
(b)	n-Hexane
(c)	Organophosphates
(d)	Drug-induced
	(i) Isoniazid



(ii) Metronidazole
(iii) Nitrofurantoin
(iv) Chloroquine/hydroxychloroquine
(v) Lithium
(vi) Chemotherapy
(xx) Other
(xx) Other
iv. Infectious
(a) Diphtheria
(b) HIV
(c) Leprosy
(d) Lyme disease
(e) Syphilis
(xx) Other
c. Dorsal root ganglion disorders
i. Nutritional/toxic, including hypervitaminosis B6
ii. Autoimmune/inflammatory
(a) Hu antibody syndrome
(b) Connective tissue disease (Sjögren syndrome)
iii. Friedreich ataxia
iv. Idiopathic
d. Small fiber neuropathy
E. Neuromuscular junction transmission disorders
01. Myasthenia gravis
02. Lambert-Eaton myasthenic syndrome
03. Botulism
04. Congenital/hereditary myasthenia
05. Medication-induced
XX. Other
F. Muscle disorders
01. Hereditary
a. Muscular dystrophies
i. Duchenne/Becker
ii. Facioscapulohumeral
iii. Limb-girdle
(a) Type 1
(b) Type 2
iv. Myotonic
(a) Myotonic dystrophy 1 (including distal presentation)
(b) Myotonic dystrophy 2
v. Oculopharyngeal



	as Challe to the least of the l
vi.	Myofibrillar (including distal presentation)
vii.	Congenital muscular dystrophy
	nital myopathies
i.	Central core
ii.	Nemaline
iii.	Centronuclear/myotubular (including distal presentation)
XX.	Other
c. Metab	olic myopathies
i.	Mitochondrial
	(a) Myoclonic epilepsy with ragged red fibers (MERRF)
	(b) Mitochondrial myopathy, lactic acid, and stroke (MELAS)
	(c) Kearns-Sayre syndrome
	(xx) Other
ii.	Glycogenoses
	(a) Pompe disease/Acid maltase deficiency
	(b) Myophosphorylase deficiency (McArdle disease)
	(c) Other
iii.	Lipidoses
	(a) Carnitine deficiency
	(b) Carnitine palmitoyltransferase 2 deficiency (CPT2)
	(c) Other
d. Period	ic paralyses/channelopathies
i.	Hypokalemic
ii.	Hyperkalemic
iii.	Andersen-Tawil syndrome
iv.	Nondystrophic myotonias
02. Acquired	
a. Inflami	matory myopathies
i.	Polymyositis
ii.	Dermatomyositis
iii.	Inclusion body myositis
	(a) Sporadic (including distal presentation)
	(b) Hereditary (including distal presentation)
iv.	Sarcoidosis
V.	HIV
	illness myopathy
c. Toxic/o	drug-induced myopathy
i.	HMG-CoA reductase
ii.	Alcohol
iii.	Chloroquine/hydroxychloroquine
iv.	Corticosteroids



v. Colchicine
vi. Antiretroviral medications
d. Metabolic/endocrine
i. Hypothyroid
ii. Hyperthyroid
iii. Hypokalemic
iv. Cushing disease
e. Necrotizing autoimmune myopathy
i. Anti-HMG-CoA reductase myopathy
ii. Anti-signal recognition particle (anti-SRP)
03. Rhabdomyolysis
G. Hyper-excitability disorders
01. Stiff-person syndromes
02. Potassium channelopathies (Isaacs syndrome)
H. Autonomic dysfunction in neuromuscular diseases
01. Autoimmune autonomic neuropathy and ganglionopathy (including Sjögren syndrome)
02. Guillain-Barré syndrome (autonomic manifestations)
03. Paraneoplastic autonomic neuropathies
04. Fabry disease
05. Autonomic neuropathies due to infectious disease
a. Chagas disease
b. Leprosy
c. Diphtheria
d. HIV
06. Diabetes (autonomic manifestations)
07. Amyloidosis
08. Adie syndrome
09. Small fiber polyneuropathy (autonomic manifestations)
10. Toxic neuropathies
a. Vacor
b. Hexane
c. Ciguatoxin
d. Vincristine
e. Cisplatin, paclitaxel
f. Heavy metals (arsenic, mercury, thallium)
g. Postural orthostatic tachycardia syndrome (POTS)
xx. Other
XX. Other
07. Movement disorders
A. Parkinson disease and parkinsonism
01. Neurodegenerative



a Idianathia Daukinaan diaaan
a. Idiopathic Parkinson disease
i. Dementia with Lewy bodies
b. Multiple system atrophy
c. Progressive supranuclear palsy
d. Corticobasal degeneration
02. Post-traumatic parkinsonism
03. Vascular parkinsonism
04. Drug-induced parkinsonism
05. Hydrocephalus and normal-pressure hydrocephalus
06. Juvenile parkinsonism
B. Tremor
01. Essential tremor
02. Physiological tremor
03. Drug-induced tremor
C. Chorea
01. Huntington disease
02. Sydenham chorea
03. Drug-induced chorea
04. Chorea gravidarum
05. Neuroacanthocytosis
D. Ballism and athetosis
E. Dystonia
01. Focal dystonia
a. Genetic
b. Nongenetic
02. Generalized dystonia
a. Genetic
b. Nongenetic
03. Dopa-responsive dystonia
XX. Other
F. Wilson disease
G. Neuroleptic-induced syndromes, acute and chronic
01. Acute dystonic reaction
02. Tardive syndromes
a. Tardive dyskinesia
b. Tardive dystonia
c. Tardive akathisia
H. Tic disorders
01. Tourette syndrome
02. Other
I. Myoclonus



		01. Essential myoclonus
		02. Post-hypoxic myoclonus
	J.	1 /
		01. Hemifacial spasm
		02. Dyskinesias
		03. Restless legs syndrome
		04. Automatisms
	K.	
		01. Spinocerebellar ataxias
		02. Friedreich ataxia
		03. Vitamin
		04. Paroxysmal ataxia
	L.	Functional movement disorders
		01. Tremor
		02. Dystonia
		03. Gait disturbance and ataxia
	M.	Critical care
		01. Acute parkinsonism
		02. Neuroleptic malignant syndrome
		03. Serotonin syndrome
		04. Dystonic storm
		05. Ballism
		06. Tic status
08.	Demy	elinating diseases
	A.	Multiple sclerosis and variants
	В.	Neuromyelitis optica
	C.	Acute disseminated encephalomyelitis and variants
	D.	Transverse myelitis
	XX.	Other
09.	Neuro	oinfectious diseases
	A.	Bacterial infections
		01. Meningitis
		a. Neonatal
		i. E. coli
		ii. Streptococcus
		iii. Listeria
		xx. Other
		b. Childhood
		i. Hemophilus influenza
		ii. Streptococcus pneumonia
		iii. Other
-		



c. Adolescent
i. Neisseria meningitis
ii. Other
d. Adult
i. Streptococcus pneumonia
ii. Listeria
iii. Other
02. Brain and spine abscess
B. Fungal infections
01. Meningitis
a. Cryptococcus
b. Histoplasmosis
c. Coccidiomycosis
xx. Other
02. Cerebritis
a. Aspergillosis
b. Phycomycosis
c. Other
C. Mycobacteria, including tuberculosis
D. Viral infections
01. Meningitis
02. Encephalitis and myelitis
a. West Nile virus
b. Herpesvirus
i. Simplex
ii. Varicella zoster
iii. HHV-6
xx. Other
c. Arbovirus
d. Rabies
e. HIV
f. Progressive multifocal leukoencephalopathy
g. Polio
i. Acute flaccid paralysis/Polio-like syndrome
h. Cytomegalovirus
i. Measles
xx. Other
E. Protozoan infections
01. Toxoplasmosis
02. Naegleria
03. Trypanosomiasis



		Other
F.		ic infections
		Cysticercosis
	02.	Malaria
	03.	Other
G.		nfections (e.g., Creutzfeldt-Jakob disease (CJD), others)
H.		ectious causes of meningitis
l.		ic infections with neurologic effects
		Lyme disease
		Syphilis
	03.	Diphtheria
	04.	Tetanus
	05.	Whipple disease
	06.	Leprosy
	XX.	Other
10. Brain		nal trauma and spinal cord diseases
A.	Brain t	
	01.	Cerebral concussion, including chronic traumatic encephalopathy
	02.	Diffuse axonal injury
		Cerebral contusion
	04.	Traumatic hemorrhage
		a. Epidural hematoma
		b. Subdural hematoma
		c. Traumatic subarachnoid hemorrhage
В.	Spinal	
		Spinal cord contusion and transection
		Spinal epidural hematoma
C.		umatic spinal cord disorders
		Spinal cord/myelopathy (e.g., compression, other)
	02.	Spinal cord herniation
	03.	Associated autonomic disorders
	04.	Cauda equina (e.g., compression, other)
	05.	Spinal cord infarction
	06.	Vascular myelopathies
	07.	Spinal cord vascular malformations
	XX.	Other (e.g., hereditary spastic paraparesis)
D.		cidental trauma in children
E.	•	neuropathy
	•	Ilmologic and neuro-otologic disorders
Α.		ophthalmology
	01.	Disorders of the optic nerve



	a.	Vascular (e.g., anterior ischemic optic neuropathy)
	b.	Inflammatory (e.g., optic neuritis)
	c.	Toxic and nutritional optic nerve disease
	d.	Inherited (e.g., Leber optic atrophy)
	e.	Papilledema and pseudopapilledema
	f.	Optic nerve tumor
02.	Disor	ders of the retina
	a.	Retinal artery occlusion, including Susac syndrome
	b.	Retinal venous occlusion
	c.	Retinal degenerations
	d.	Phakomatoses
03.	Othe	r lesions of optic pathways
	a.	Optic chiasm
	b.	Optic tracts
	C.	Optic radiations
	d.	Visual cortex, including visual agnosias and cortical blindness
04.	Disor	ders of the pupil
	a.	Horner syndrome
	b.	Argyll-Robertson pupil
	c.	Tonic pupil
05.	Disor	ders of ocular motility
	a.	Disorders of supranuclear control of eye movements
		i. Horizontal gaze paresis, including internuclear ophthalmoplegia (INO) and one-and-
		a-half syndrome
		ii. Upgaze paresis, including Parinaud syndrome
		iii. Downgaze paresis
	b.	Disorders of cranial nerves 3,4, 6, and their nuclei
	c.	Nystagmus
	d.	Cavernous sinus disorders
	e.	Extraocular disorders
06.	Intra	ocular manifestations of stroke
B. Neuro-	otolog	şy
01.	Vesti	bular disease
	a.	Benign paroxysmal positional vertigo
	b.	Ménière disease
	C.	Acute labyrinthitis
	d.	Toxic vestibulopathy
	e.	Cerebellopontine angle tumors
	f.	Central vertigo, including disembarkment syndrome
	g.	Benign paroxysmal vertigo of childhood
02.		ing loss, including inherited and acquired



			a. Sensorineural
			b. Conductive
		03.	
		XX.	Other, including pulsatile tinnitus
12. N	∕letal		eases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents
	A.	Metab	olic diseases
			Hypoxic-ischemic encephalopathy
		02.	Disorders of glucose metabolism, including hypoglycemia, diabetic ketoacidosis, and nonketotic
			hyperglycemia
		03.	Hepatic encephalopathy
		04.	Uremic encephalopathy, including dialysis dementia and dialysis dysequilibrium syndrome
		05.	Disorders of sodium, potassium, and water metabolism, including hyponatremia, hypernatremia,
			hypokalemia, and hyperkalemia
		06.	Disorders of calcium and magnesium metabolism, including hypocalcemia, hypercalcemia,
			hypomagnesemia, and hypermagnesemia
		07.	Endocrine diseases, including those of thyroid, parathyroid, adrenal, and pituitary glands
			(including pituitary apoplexy)
		08.	Drug overdose
	В.		onal deficiency states
		01.	B vitamins
			a. Thiamine (including Wernicke encephalopathy)
			b. Niacin
			c. Pyridoxine
			d. Cobalamin
			e. Folic acid
		02.	Vitamin E
		03.	Vitamins A and D
		XX.	Other
			a. Copper deficiency
			b. Protein calorie malnutrition
			c. Strachan syndrome and related disorders
			d. Complications of bariatric surgery
	C.		drugs, and physical agents
		01.	Exposure to chemicals
			a. Acrylamide
			b. Carbon disulfide
			c. Ethylene oxide
			d. Hexacarbon solvents
			e. Organophosphates
			f. Toluene
			xx. Other



02.	Exposure to metals
02.	
	a. Aluminum b. Arsenic
	e. Mercury
	f. Thallium
	g. Tin
02	xx. Other
03.	Effects of drug abuse
	a. Opioids
	b. Cocaine
	c. Amphetamines
	d. Sedative-hypnotics
	e. Inhalants
	f. Hallucinogens
	xx. Other
04.	
	a. Acute alcoholic intoxication
	b. Alcohol withdrawal syndromes
	c. Effects related to nutritional deficiency
	d. Effects of unknown etiology (e.g., Marchiafava-Bignami disease)
	e. Effects of alcohols other than ethanol (e.g., methyl alcohol and ethylene glycol)
05.	Effects of ionizing radiation
	a. Encephalopathy
	b. Myelopathy
	c. Plexopathy
06.	Hypothermia and hyperthermia
07.	Electric current and lightning
08.	Animal and insect neurotoxins
	a. Snakes
	b. Spiders
	c. Scorpions
	d. Tick paralysis
09.	Marine neurotoxins
	a. Ciguatera fish poisoning
	b. Puffer fish poisoning
10.	Plant neurotoxins
	a. Mushroom poisoning
	b. Other
D. latroge	nic/therapeutic drugs



13. Neuro-oncologic disorders A. Neoplasms O1. Primary a. Primitive neuroectodermal tumors i. Medulloblastoma ii. Retinoblastoma b. Gliomas i. Astrocytoma (a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma	A. Neoplasms 01. Prir	nary
01. Primary a. Primitive neuroectodermal tumors i. Medulloblastoma ii. Retinoblastoma b. Gliomas i. Astrocytoma (a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma	01. Prir	·
i. Medulloblastoma ii. Retinoblastoma b. Gliomas i. Astrocytoma (a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma	а	Primitive neuroectodermal tumors
ii. Retinoblastoma b. Gliomas i. Astrocytoma (a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		
b. Gliomas i. Astrocytoma (a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		i. Medulloblastoma
i. Astrocytoma (a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		ii. Retinoblastoma
(a) Low-grade (i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma	b	Gliomas
(i) Pilocytic astrocytoma (ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		i. Astrocytoma
(ii) Astrocytoma (b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		······································
(b) High-grade (i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		(i) Pilocytic astrocytoma
(i) Anaplastic astrocytoma (ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		(ii) Astrocytoma
(ii) Glioblastoma ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		
ii. Oligodendroglioma (a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		
(a) Oligodendroglioma (b) Anaplastic oligodendroglioma iii. Ependymoma		· · ·
(b) Anaplastic oligodendroglioma iii. Ependymoma		
iii. Ependymoma		
(a) Fpendymoma		1 ,
		(a) Ependymoma
(b) Anaplastic ependymoma		
(c) Myxopapillary ependymoma		
c. Neuronal tumors	С	
i. Central neurocytoma		
ii. Dysembryoplastic neuroectodermal tumor (DNET)		, , , ,
iii. Gangliocytoma iv. Ganglioglioma		
	4	
d. Meningioma e. Nerve sheath tumors		
i. Schwannoma		
ii. Neurofibroma		
f. Primary CNS lymphoma	f	
g. Craniopharyngioma		
h. Pituitary adenoma	-	
i. Pineal tumors		•
j. Choroid plexus tumors		
02. Secondary	,	•
a. Metastatic intraparenchymal		,
b. Meningeal carcinomatosis		
c. Metastases to spine and skull		
B. Hereditary tumor syndromes		
01. Neurofibromatosis		



		02.	Von Hippel-Lindau disease
		03.	Tuberous sclerosis
		04.	Cowden syndrome
		05.	Multiple endocrine neoplasms (MEN)
	C.	Non-m	etastatic neurologic complications of systemic cancer
		01.	Vascular disease
	D.	Neurol	ogic complications of cancer treatment
		01.	Radiation therapy
			a. Radiation necrosis
			b. Secondary neoplasms
		02.	Chemotherapy
14. I	Behav	ioral ne	urology and neurocognitive disorders
	A.	Deliriu	m, dementia, and other cognitive disorders
		01.	Delirium
			a. Delirium due to a medical condition
			b. Substance intoxication delirium
			c. Substance withdrawal delirium
			d. Delirium due to multiple etiologies
			xx. Other
		02.	Dementia
			a. Mild cognitive impairment
			b. Alzheimer disease
			c. Vascular dementia
			d. HIV disease
			e. Traumatic brain injury
			f. Frontotemporal disorders
			g. Dementia due to a medical condition
			h. Substance/medication-induced dementia
			i. Multiple etiologies, including metabolic, endocrine, toxic, and neoplastic/paraneoplastic
			j. Primary progressive aphasia
			k. Dementia with Lewy bodies
			I. Cerebral small vessel disease
			xx. Other
		03.	Amnestic disorders (including transient global amnesia)
		XX.	Other
	В.	Neuro	developmental disorders
		01.	Learning disorders
		02.	Communication disorders
		03.	Autism spectrum disorders
		04.	Attention-deficit and disruptive behavior disorders
		XX.	Other (global developmental delay/intellectual disability)
L			



		Himbon	acutical formation and aliminal arm due nace
	C.		cortical function and clinical syndromes
			Frontal lobe syndromes
			Aphasia
			Apraxia
		04.	Neglect
		05.	Agnosia
		06.	Disconnection syndromes
	D.		ion of mental status/encephalopathy/coma/brain death
	E.		bulbar affect/pseudobulbar palsy
	XX.	Other	
15.	Psychi	iatric dis	
	Α.		phrenia and other psychotic disorders
			Schizophrenia
		02.	1 /
		03.	-,
		04.	Substance/medication-induced psychotic disorder
		XX.	
	В.	Depres	sive disorders
		01.	Major depressive disorder
		02.	
		03.	Depressive disorder due to another medical condition
		XX.	Other
	C.	Bipolar	and related disorders
		01.	Bipolar I disorder
		02.	Bipolar II disorder
	D.	Anxiety	y disorders
		01.	Social anxiety
		02.	Panic disorder
		03.	Generalized anxiety disorder
		04.	Anxiety disorder due to another medical condition
		05.	Substance/medication-induced anxiety disorder
		XX.	Other
	E.	Obsess	ive-compulsive and related disorders
	F.		c symptom and related disorders
		01.	Functional neurological symptom disorder (conversion disorder)
		02.	Pain disorder
		03.	Somatic symptom disorder
		04.	Illness anxiety disorder
		05.	Factitious disorders
		XX.	Other
	G.	Trauma	a- and stressor-related disorders



		01.	
		02.	
		03.	Adjustment disorder
	Н.		disorders
		01.	Sexual pain disorders
		02.	Sexual dysfunction due to a general medical condition
		03.	Other
	I.	Feedin	g and eating disorders
		01.	Anorexia nervosa
		02.	Bulimia nervosa
	J.	Elimina	ation disorders
	K.	Person	ality disorders
	XX.	Other	osychiatric disorders
16.	Auton	omic ne	ervous system disorders
	A.	Disord	ers of orthostatic tolerance
		01.	Orthostatic hypotension
		02.	Postural tachycardia syndrome (POTS)
		03.	Neurally mediated syncope
			a. Central causes (emotional)
			b. Reflex causes
			i. Carotid sinus stimulation
			ii. Micturition, defecation, coughing
			iii. Hemodynamic stress
	В.	Autono	omic dysfunction in CNS disorders
		01.	Lewy body disorders
		02.	Multiple system atrophy
		03.	Tauopathies
		04.	Pure autonomic failure
		05.	Multiple sclerosis
		06.	Stroke
	C.		ers of sweating and thermoregulation
		01.	
		02.	
		03.	
		04.	
	D.	Autono	omic disorders of the urogenital system
		01.	
		02.	•
	E.		omic disorders of the gastrointestinal tract
			Achalasia
		02.	
			•



			Cyclic vomiting syndrome
		04.	Intestinal pseudo-obstruction
		05.	-
	F.		al sensory disorders
		01.	The second secon
			a. Disorders of taste
			b. Associated with glossopharyngeal neuralgia
		02.	, ,
			(including autonomic dysreflexia)
		03.	Disorders of central visceral sensation: insular cortex stroke
17.	Quest	ions not	associated with a specific neurologic disorder
	A.	Norma	l anatomy, process, neurophysiology
	В.	Pharm	acology
	C.	Medica	al-legal, public policy/regulatory factors, professional practice
	D.	Develo	pment through the life cycle: developmental processes, tasks, crises, transitions
		01.	Childhood (school entry, peer relations, individuation)
		02.	Adulthood (employment, parenting, acquisition/loss of specific capacities)
		03.	Late life (cognition, physical endurance, loss of specific capacities)
	E.	Proced	ures/procedural safety
	F.	Norma	l test results, findings, variants, artifacts, and methods
18.	Neuro	oimmun	ologic and paraneoplastic CNS disorders
	A.	CNS va	sculitis and microangiopathies
		01.	Primary angiitis of the CNS
		02.	Secondary CNS vasculitis
			a. Systemic vasculitides (giant cell arteritis, polyarteritis nodosa, microscopic polyangiitis,
			Behçet disease)
			b. Systemic autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis,
			Sjögren syndrome, sarcoidosis)
			c. Infectious vasculitis (varicella zoster)
			d. Substance-induced vasculitis (amphetamines, cocaine)
		03.	Microangiopathies (Susac syndrome, Sneddon syndrome)
	В.	Neuroi	mmunologic/paraneoplastic CNS syndromes
		01.	Cerebellar syndromes
		02.	Encephalitis/encephalomyelitis (anti-NMDA, anti-IL2, limbic, other)
		03.	Opsoclonus-myoclonus
		04.	Epilepsy
		XX.	Other



Number o	of items:	400
		Dimension 2
		Physician Competencies and Mechanisms
A. Neur	oscience	and mechanism of disease
01.	Neuroa	natomy
	a.	Cerebral cortex
	b.	Connecting systems
	c.	Basal ganglia/thalamus
	d.	Brainstem
	e.	Cerebellum
	f.	Cranial nerves
	g.	Spinal cord
	h.	Spinal roots/peripheral nerves
	i.	Ventricular system, CSF
	j.	Vascular
	k.	Neuromuscular junction/muscle
	l.	Autonomic nervous system
	m.	Embryology and neural development
	n.	Pain pathways
	0.	Radiologic anatomy, cerebral blood vessels (angiography or MRA)
	p.	CSF anatomy, physiology, normal and abnormal patterns (cellular, chemical, enzymatic, serologic)
	q.	Meninges
	r.	Plexus
	XX.	Other
02.	Neurop	athology
	a.	Basic patterns of reaction
	b.	Cerebrovascular disease
	C.	Trauma (cranial and spinal)
	d.	Metabolic/toxic/nutritional diseases
	e.	Infections
	f.	Demyelinating diseases/leukodystrophies
	g.	Neoplasms
	h.	Congenital/developmental anomalies
	i.	Degenerative/heredodegenerative disorders
	j.	Myopathies
	k.	Peripheral nerve
	l.	Neuromuscular junction disorders
	m.	Radiologic pathology pertinent to assigned pathology sections
	n.	Medium and large-vessel vasculitis
	XX.	Other
03.	Neuroc	hemistry



a.	Carbohydrate metabolism
b.	Lipid metabolism
C.	Protein metabolism
d.	Neurotransmitters
e.	Axonal transport
f.	Energy metabolism
g.	Blood-brain barrier
h.	Biochemistry of membranes/receptors/ion channels
i.	Neuronal excitation
j.	Vitamins (general aspects)
k.	Inborn errors of metabolism
I.	Electrolytes and minerals
m.	Neurotoxins
n.	Free radical scavengers
0.	Excitotoxicity
p.	Normal CSF constituents and volume
XX.	Other
04. Neurop	hysiology
a.	
b.	Synaptic transmission
C.	Sensory receptors and perception
d.	Special senses
e.	Reflexes
f.	Segmental and suprasegmental control of movement
g.	Cerebellar function
h.	Reticular system: mechanisms of sleep and arousal, consciousness, circadian rhythms
i.	Rhinencephalon, limbic system, visceral brain
i	Learning and memory
k.	Cortical organization and function
K.	Cerebral blood flow
m.	Autonomic function
n.	Blood-brain barrier
0.	Neurophysiology of the visual system
p.	Neurophysiology of the visual system Neurophysiology of hearing and vestibular function
q.	Physiology of pain
r.	Physiology of peripheral nerve and muscle
	Coagulation cascade
s.	Metabolic and cellular consequences of ischemia
	Inflammation and stroke
u.	Other
XX. 05. Neuroir	nmunology/neuroinfectious disease
a.	rathogenesis of illultible scietosis



	b.	Pathogenesis of diseases (including prion diseases)		
	c. Immunotherapy in multiple sclerosis, myasthenia gravis, and other neurologic disorders			
	d.	Antibody mediated disorders		
	XX.	Other		
06.	Neurog	enetics/molecular neurology, and neuroepidemiology		
	a.	Mendelian-inherited diseases		
	b.	Other modes of inheritance		
	C.	Mitochondrial disorders		
	d.	Nucleotide repeat disorders		
	e.	Channelopathies		
	f.	Genetics of epilepsy		
	g.	Risk factors in neurologic disease		
	h.	Demographics of neurologic disease		
07.	Neuroe	ndocrinology		
	a.	Thyroid gland		
	b.	Cushing syndrome		
	C.	Corticosteroids		
	d.	Growth hormones		
	e.	Hypothalamic function		
	f.	Adrenal gland		
	g.	Pituitary gland		
	h.	Prolactin		
	i.	Androgen		
	j.	Estrogen		
	k.	Progesterone		
08.	Pathopl	hysiology		
	a.	Epilepsy		
	b.	Vascular		
	c.	Brain edema and increased ICP		
	d.	Neuromuscular		
	XX.	Other		
B. Clinic	al aspect	ts of neurologic disease		
01.	Epidem			
02.	Risk fac	7,		
	a.	Risk factors for stroke		
	b.	Risk factors for epilepsy		
03.	Signs ar	nd symptoms		
04.	Comorb	, ,		
05.		of illness		
06.	Prognos			
07.	Localiza			
08.		ncy/peripartum		
	<u> </u>			



10. Quality of life C. Diagnostic procedures O1. Neuroimaging a. Structural imaging (computed tomography, magnetic resonance imaging, and others) b. Vascular imaging (computed tomography, computed tomography, magnetic resonance angiography, ultrasound) c. Functional neuroimaging, including fMRI, SPECT, PET O2. EEG (routine EEG, LTME, subdural and cortical EEGs) O3. Magnetoencephalography O4. Evoked potentials, including intraoperative monitoring O5. Sleep studies O6. EMG/NCS, including single fiber EMG (SFEMG) O7. Autonomic function testing O8. CSF examination/lumbar puncture O9. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of Special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring iii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes		00	Computerations of illusors			
C. Diagnostic procedures 01. Neuroimaging a. Structural imaging (computed tomography, magnetic resonance imaging, and others) b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, ultrasound) c. Functional neuroimaging, including fMRI, SPECT, PET 02. EEG (routine EEG, LTME, subdural and cortical EEGS) 03. Magnetoencephalography 04. Evoked potentials, including intraoperative monitoring 05. Sleep studies 06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring iii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes		09.	Complications of illness			
a. Structural imaging (computed tomography, magnetic resonance imaging, and others) b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, ultrasound) c. Functional neuroimaging, including fMRI, SPECT, PET OZ. EEG (routine EEG, LTME, subdural and cortical EEGs) O3. Magnetoencephalography O4. Evoked potentials, including intraoperative monitoring O5. Sleep studies O6. EMG/NCS, including single fiber EMG (SFEMG) O7. Autonomic function testing O8. CSP examination/lumbar puncture O9. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease seventy/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interractions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes	_		· ·			
a. Structural imaging (computed tomography, magnetic resonance imaging, and others) b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, utrasound) c. Functional neuroimaging, including fMRI, SPECT, PET O2. EEG (routine EEG, LTME, subdural and cortical EEGS) O3. Magnetoencephalography O4. Evoked potentials, including intraoperative monitoring O5. Sleep studies O6. EMG/NCS, including single fiber EMG (SFEMG) O7. Autonomic function testing O8. CSF examination/lumbar puncture O9. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes	С.		•			
b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, ultrasound) c. Functional neuroimaging, including fMRI, SPECT, PET O2. EEG (routine EEG, LTME, subdural and cortical EEGs) O3. Magnetoencephalography O4. Evoked potentials, including intraoperative monitoring O5. Sleep studies O6. EMG/NCS, including single fiber EMG (SFEMG) O7. Autonomic function testing O8. CSF examination/lumbar puncture O9. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotriargy a. Drugs for migraine and other headache syndromes		01.	·			
resonance angiography, ultrasound) C. Functional neuroimaging, including fMRI, SPECT, PET O2. EEG (routine EEG, LTME, subdural and cortical EEGS) O3. Magnetoencephalography O4. Evoked potentials, including intraoperative monitoring O5. Sleep studies O6. EMG/NCS, including single fiber EMG (SFEMG) O7. Autonomic function testing O8. CSF examination/lumbar puncture O9. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
c. Functional neuroimaging, including fMRI, SPECT, PET 02. EEG (routine EEG, LTME, subdural and cortical EEGS) 03. Magnetoencephalography 04. Evoked potentials, including intraoperative monitoring 05. Sleep studies 06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
02. EEG (routine EEG, LTME, subdural and cortical EEGs) 03. Magnetoencephalography 04. Evoked potentials, including intraoperative monitoring 05. Sleep studies 06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
03. Magnetoencephalography 04. Evoked potentials, including intraoperative monitoring 05. Sleep studies 06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes		02				
04. Evoked potentials, including intraoperative monitoring 05. Sleep studies 06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
05. Sleep studies 06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring iii. Drug level fluctuations iiii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
06. EMG/NCS, including single fiber EMG (SFEMG) 07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
07. Autonomic function testing 08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
08. CSF examination/lumbar puncture 09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring iii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
09. Laboratory studies 10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
10. Neuropsychological and cognitive testing 11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes			· · · · · · · · · · · · · · · · · · ·			
11. Cardiac testing 12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes			,			
12. Skin/nerve/muscle biopsy 13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
13. Genetic testing 14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
14. Neurophysiologic properties and instrumentation 15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
15. Testing of special senses (e.g., hearing, vision) 16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring iii. Drug level fluctuations iiii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
16. Clinical/disease severity/rating scales 17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
17. Pulmonary function test 18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management O1. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
18. Systemic imaging (e.g., CT, MRI, PET) XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
XX. Other D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes			·			
D. Treatment/Management 01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
01. General principles of neuropharmacology a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes	D.					
a. Neuropharmacokinetics/neuropharmacodynamics b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes			•			
b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal/contraindications c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes		01.	· · · · · · · · · · · · · · · · · · ·			
c. Drug interactions d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
d. Pregnancy i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
i. Teratogenicity/neurodevelopmental effects in offspring ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) O2. Pharmacotherapy a. Drugs for migraine and other headache syndromes			<u>·</u>			
ii. Drug level fluctuations iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
iii. Breastfeeding e. Age, gender, and ethnicity issues f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes			•			
f. Pharmacogenomics g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes			e. Age, gender, and ethnicity issues			
g. Mechanisms of action h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
h. Drug management decisions (initiation, continuation, discontinuation) 02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
02. Pharmacotherapy a. Drugs for migraine and other headache syndromes						
		02.	Pharmacotherapy			
			a. Drugs for migraine and other headache syndromes			
b. Analgesics (nonnarcotic, narcotic, etc.)			b. Analgesics (nonnarcotic, narcotic, etc.)			



	C.	Antiseizure medications
	d.	Drugs for sleep disorders
	e.	Drugs for cerebrovascular disease, including antiplatelet agents, anticoagulants, and
		thrombolytics
	f.	Drugs for neuromuscular disorders
	g.	Drugs for movement disorders
	h.	Drugs for multiple sclerosis (disease-modifying therapy and symptomatic treatment)
	i.	Drugs for psychiatric disorders (sedative-hypnotics, antianxiety agents, antidepressants,
		antipsychotics)
	j.	Vitamins/minerals/nutrients
	k.	Immunomodulatory agents, including oral medications, prednisone, IV Ig, and plasma exchange
	I.	Antimicrobial agents
	m.	Drugs used for increased intracranial pressure and for brain/spinal cord edema
	n.	Drugs for autonomic dysfunctions
	0.	Drugs for dementia/cognition/alertness
	p.	Spasticity treatments
	q.	Antineoplastic agents
	r.	Monotherapy vs polytherapy
	S.	Hormonal therapies
	XX.	Other
		i. Sedation
		ii. Stimulants
		iii. Antidotes
03.	Endova	scular treatment
04.	Neuron	nodulation
	a.	Vagus nerve stimulation (VNS)
	b.	Deep brain stimulation (DBS)
	C.	Transcutaneous electrical nerve stimulation (TENS)
	d.	Spinal cord stimulation (SCS)
	e.	Transcranial magnetic stimulation (TMS)
	f.	Electroconvulsive therapy (ECT)
	g.	Responsive neurostimulation (RNS)
	XX.	Other
05.	Critical	
06.		I treatment/interventions
07.		on therapy
08.	Rehabil	• • • • • • • • • • • • • • • • • • • •
	a.	Exercise
	b.	Assistive devices
	C.	Assistive devices Assistive technologies
	c. d.	Braces
	e.	Physical therapy and occupational therapy
	е.	Thysical therapy and occupational therapy



		f. Pulmonary
		g. Speech/swallowing
		h. Nutrition management
		i. Principles of neurorehabilitation (e.g. regeneration and plasticity)
		j. Functional assessment
	09.	Psychotherapy, biofeedback etc.
	10.	Reassurance, observation, lifestyle modification, etc.
	11.	Specific dietary treatment
	12.	Genetic counseling
	13.	Complications of management
	14.	Gene therapy/enzyme replacement therapy/stem cell replacement
	15.	Nonsurgical/nonpharmacological
	XX.	Other
E. 1		personal and communications skills
	01.	Communication with patients
		a. Communication of progress
	02.	Communication with patients' families
	03.	Communication with other professionals
	04.	Communication with the healthcare team
	05.	Communication with the public
	06.	Management of conflict
	07.	Common errors in communication
	08.	Patient and family education
F. I	Profe	ssionalism
	01.	Professional behavior
	02.	Adherence to ethical principles (e.g., informed consent, research issues, clinical care)
	03.	Participation in the professional community
	04.	Sensitivity to diverse patient populations
	05.	End-of-life issues and brain death
	06.	Fatigue management/burnout
G. I	Pract	ice-based learning and improvement
	01.	Development and execution of lifelong learning
		a. Self-assessment and self-improvement
		b. Use of evidence-based guidelines
		c. Critical review of scientific literature
	02.	Formal practice-based quality improvement
н. 9	Syste	ms-based practice
	01.	Patient safety and the healthcare team
		a. Medical errors and their prevention
		b. Communication in patient safety
		c. Regulatory and educational activities related to patient safety
	02.	Resource management



	a.	Parity
	b.	Access to care
	c.	Negotiation with payers
03. C	Commu	nity-based care
	a.	Community-based programs
	b.	Prevention
	c.	Recovery and rehabilitation
	d.	Knowledge of the legal aspects of neurological practice
04. R	Referral	for appropriate consultation/decision making
05. V	Working	g with local and national disease-based and advocacy groups